Editorial

Traditional drug discovery is slow, costly, and prone to high attrition, with only a fraction of candidate compounds surviving the arduous journey from bench to bedside. Artificial intelligence (AI) and machine learning (ML) are now being positioned as transformative forces in this domain, capable of accelerating target identification, optimizing lead molecules, and predicting safety profiles